Treating hearts and minds: adverse cardiovascular effects of psychiatric medications [PDF]
Therapeutic Advances in Drug SafetyCardiovascular disease (CVD) is one of the leading causes of death in patients with severe mental illness (SMI), being ~3.3 times higher than in the general population.
Asdaq Shabbir Raja +5 more
doaj +2 more sources
Molecular docking approach of monoamine oxidase B inhibitors for identifying new potential drugs: Insights into drug-protein interaction discovery [PDF]
Journal of Cell and Molecular Research, 2013 Monoamine oxidase (EC, 1.4.3.4) or amine oxidoreductase catalyzes the oxidative deamination of biogenic amines. Abnormal action of the monoamine oxidase B has been associated with neurological dysfunctions including parkinson´s disorder.
Salimeh Raeisi
doaj +1 more source
Monoamine oxidase inhibitors and neuroprotective mechanisms
Psychiatry and Clinical Psychopharmacology, 2021 There has been a resurgence of interest in recent years in monoamine oxidase inhibitors, primarily because of the demonstrated neuroprotective and/ or neurorescue properties of several of these drugs in a variety of toxic situations in vivo and in vitro.
Glen Baker +4 more
doaj +1 more source
PART 1: DESIGN, SYNTHESIS AND EVALUATION OF NEW SITE-SPECIFIC MONOAMINE OXIDASE INHIBITORS [PDF]
Bulletin of Pharmaceutical Sciences. Assiut University, 1998 Certain new monoamine oxidase inhibitors (MAOIs) containing a pyridinium moiety as an integral part of their structures (Q) were designed. The quaternaries, their corresponding 1,4-dihydroxypyridine derivatives (CDS) and their parent pyridine compounds ...
N. Bodor +4 more
doaj +1 more source
3D-QSAR and in-silico Studies of Natural Products and Related Derivatives as Monoamine Oxidase Inhibitors [PDF]
Current Neuropharmacology, 2018 Anurag Khatkar, Neelam Malik
exaly +2 more sources
Jurnal Kimia Riset, 2023 Kratom (Mitragyna speciosa Korth) is a tropical plant originating from Southeast Asia that predominantly contains alkaloid compounds and can potentially maintain levels of monoamine compounds in the body to treat depression.
Dandi Irawan +2 more
doaj +1 more source
Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of d-amino acid oxidase
Results in Chemistry, 2022 A recent study has found that phenothiazine, anthraquinone and related tricyclic derivatives are good potency inhibitors of the monoamine oxidase (MAO) enzymes.
Roslyn Lefin +3 more
doaj +1 more source
Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson’s Disease: From Bench to Bedside [PDF]
Current Neuropharmacology, 2019 Ferdinando Nicoletti +1 more
exaly +2 more sources
Antioxidants, 2023 Oxidative catabolism of monoamine neurotransmitters by monoamine oxidases (MAOs) produces reactive oxygen species (ROS), which contributes to neuronal cells’ death and also lowers monoamine neurotransmitter levels.
Ahmed H. E. Hassan +14 more
doaj +1 more source
Pathophysiology of Depression: Stingless Bee Honey Promising as an Antidepressant
Molecules, 2022 Depression is a debilitating psychiatric disorder impacting an individual’s quality of life. It is the most prevalent mental illness across all age categories, incurring huge socio-economic impacts.
Fatin Haniza Zakaria +3 more
doaj +1 more source